rwe

When Evidence Gap Becomes a Commercial Liability

The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.

AI-Powered Cohorting Is Quietly Reshaping How Real-World Evidence Gets Built

The organizations that benefit the most from AI-powered cohorting will not simply be those that move faster. They will be those that embed patient mastering and semantic rigor into reproduceable, inspectable workflows.

Leading Clinical Trial Recruitment Strategies Center Around Real-World Data

By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.

Why Digital Health Collaborations Are the Future of Medtech

Executives from Huma, Abbott, Smith & Nephew and AliveCor share how they are using real world evidence collection to support remote patient monitoring, maximize patient engagement and navigate the regulatory landscape.

Why collaboration is essential for using real world evidence in regulatory submissions underpinning remote patient monitoring

Huma plays a vital role in leveraging its digital infrastructure to help medical device companies navigate the regulatory complexities of generating RWE.

How medtech can crack the patient engagement conundrum and transform the patient experience

A look at how tapping real world evidence from medical devices and patients could be a game changer, improving patient-clinician communication, supporting earlier interventions and helping patients manage their condition.

Health equity should start at birth

Pregnant women and others able to give birth are severely underrepresented in clinical research globally. But real-world data – when relevant, reliable, and fit for the purpose of answering a given research question – can be used to generate evidence on how health interventions perform in those who are pregnant.

Rescuing cancer care from the “Black Hole” of Covid-19

With RWE helping to inform, guide, and refine ongoing protocols and pathways, we can battle Covid-19 and cancer together and be far better prepared in our response to the next pandemic.

Aetion completes $82M Series B round with $19M extension

The healthcare analytics company said it had raised the extension funding from three new investors and would use it to accelerate development of its real-world evidence technology.

FDA, Aetion team up on real-world evidence research in Covid-19

The two plan to identify and analyze sources of real-world data that they can use to characterize populations of patients with Covid-19, their use of medicines, risk factors and to characterize potential interventions.

ICER to use real-world evidence from Aetion in assessments

The health technology assessment group and the New York-based company announced their partnership Monday. ICER also plans to use RWE in assessing drugs that have accelerated FDA approval.

A study showed RWE can replicate only 15% of RCTs – is this accurate?

The primary goal of incorporating RWE into clinical research isn’t to make RCTs unnecessary or irrelevant, but rather to better understand how drugs perform in broader patient groups, among other things.

Sanofi to leverage Aetion’s data analytics platform to get real world evidence of drug efficacy

Aetion's real-world evidence platform will be integrated with Sanofi's real-world data platform called Darwin to gain a better understanding of the safety, efficacy and value of drugs while also boosting RWE as complementary to clinical trial data in the decision-making process for drug approvals.